諾唯贊(688105.SH)抗原檢測試劑盒完成醫療器械產品註冊預期用途、增加樣本類型及説明書內容的變更
格隆匯3月13日丨諾唯贊(688105.SH)公佈,公司全資子公司南京諾唯贊醫療科技有限公司於2022年3月12日取得由國家藥品監督管理局審批通過的《醫療器械註冊變更文件(體外診斷試劑)》。諾唯贊醫療生產的新型冠狀病毒抗原檢測試劑盒完成了醫療器械產品註冊預期用途、增加樣本類型及説明書內容的變更。
上述變更事項進一步響應了國家新冠疫情防控與檢測政策,有助於進一步提升公司在相關領域的競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.